Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.9%

1 terminated out of 17 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

24%

4 trials in Phase 3/4

Results Transparency

8%

1 of 12 completed with results

Key Signals

1 with results92% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (4)
P 1 (2)
P 2 (2)
P 3 (1)
P 4 (3)

Trial Status

Completed12
Withdrawn1
Not Yet Recruiting1
Terminated1
Unknown1
Recruiting1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT04244877Phase 3Withdrawn

Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility

NCT07272707Not Yet RecruitingPrimary

Psychometric Hepatic Encephalopathy Score in Prediction of Minimal Hepatic Encephalopathy in Compensated Cirrhotic Patients

NCT06538077Phase 4Recruiting

BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE

NCT04058327Completed

A Study of MHE in Patients With Liver Diseases

NCT03585257Phase 2Completed

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT04077125CompletedPrimary

Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy

NCT02767622CompletedPrimary

Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation

NCT01847651Phase 4Completed

Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate

NCT02520817CompletedPrimary

Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study

NCT01135628Not ApplicableCompleted

Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy

NCT00811434Phase 2TerminatedPrimary

Study of Lactulose in Children With Chronic Liver Disease

NCT00992290Phase 1CompletedPrimary

Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy

NCT01069133Phase 1CompletedPrimary

Study of Rifaximin in Minimal Hepatic Encephalopathy

NCT01223729Not ApplicableCompletedPrimary

Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy

NCT01083446Not ApplicableUnknownPrimary

A Nutritional Approach to Minimal Hepatic Encephalopathy

NCT00312078Not ApplicableCompleted

Effect of Yogurt on Minimal Hepatic Encephalopathy

NCT00375375Phase 4CompletedPrimary

Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life

Showing all 17 trials

Research Network

Activity Timeline